MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Myomo Total Assets 2011-2026 | MYO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Myomo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.2 M | 20.1 M | 14.7 M | 6.6 M | 8.28 M | 14 M | 1.66 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.1 M | 1.66 M | 10.8 M |
Quarterly Total Assets Myomo
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.1 M | 38.7 M | 40.9 M | 42.2 M | 16.3 M | 16.2 M | 16.5 M | 14.6 M | 17.1 M | 13.3 M | 13.7 M | 10.2 M | 12.2 M | - | 18 M | 20.1 M | 17.5 M | 17.7 M | 20.9 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 8.28 M | 8.28 M | 8.28 M | 8.28 M | 14 M | 14 M | 14 M | 14 M | 1.66 M | 1.66 M | 1.66 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 42.2 M | 1.66 M | 15.1 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
204 M | $ 31.65 | -5.55 % | $ 1.4 B |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Abiomed
ABMD
|
1.49 B | - | - | $ 17.2 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
498 M | $ 9.76 | 1.99 % | $ 701 M |  Israel |
 |
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
Apyx Medical Corporation
APYX
|
79.2 M | $ 3.92 | 12.33 % | $ 136 M | USA |
 |
Alphatec Holdings
ATEC
|
776 M | $ 17.97 | -20.68 % | $ 2.57 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
Bio-Rad Laboratories
BIO
|
9.36 B | $ 322.91 | -0.16 % | $ 9.11 B | USA |
 |
Bruker Corporation
BRKR
|
5.81 B | $ 53.33 | -2.07 % | $ 7.95 K | USA |
 |
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
39.4 B | $ 95.53 | -2.13 % | $ 141 B | USA |
 |
EDAP TMS S.A.
EDAP
|
86.1 M | $ 4.1 | 11.41 % | $ 153 M |  France |
 |
Abbott Laboratories
ABT
|
81.4 B | $ 124.29 | -1.27 % | $ 216 B | USA |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
CONMED Corporation
CNMD
|
2.31 B | $ 43.45 | 1.31 % | $ 1.34 B | USA |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
Integra LifeSciences Holdings Corporation
IART
|
4.04 B | $ 13.09 | -3.61 % | $ 1.01 B | USA |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
53.8 M | $ 28.66 | -0.49 % | $ 242 M | USA |
 |
IRIDEX Corporation
IRIX
|
34.4 M | $ 1.49 | 29.56 % | $ 24 M | USA |
 |
InMode Ltd.
INMD
|
786 M | $ 14.49 | 0.35 % | $ 1.15 B | Israel |
 |
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
6.21 B | $ 171.78 | -0.58 % | $ 12.9 B | USA |
 |
Accuray Incorporated
ARAY
|
470 M | $ 0.88 | -0.46 % | $ 90.4 M | USA |
 |
IRadimed Corporation
IRMD
|
98.3 M | $ 97.57 | -1.39 % | $ 1.24 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
473 M | $ 20.12 | 9.89 % | $ 464 M | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
39.2 M | $ 15.66 | 4.96 % | $ 423 M | USA |
 |
FONAR Corporation
FONR
|
199 M | $ 18.6 | 0.27 % | $ 122 M | USA |
 |
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
Pulmonx Corporation
LUNG
|
163 M | $ 2.0 | -2.21 % | $ 78.2 M | USA |
 |
Globus Medical
GMED
|
5.25 B | $ 91.33 | -3.28 % | $ 12.4 B | USA |
 |
Aziyo Biologics
AZYO
|
43.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Establishment Labs Holdings
ESTA
|
347 M | $ 66.18 | -3.17 % | $ 1.86 B |  Costa-rica |